MS Research Update — June 20, 2026
Updated Thesis
Morgan Stanley is a leading global financial services firm with a strong focus on wealth management and institutional securities, generating $70.6 billion in net revenues in 2025. The company benefits from a durable competitive moat driven by its fee-based wealth franchise, strong profitability with a 15.1% net margin, and steady capital returns. However, the stock is significantly overvalued, trading approximately 1803% above its fair value estimate of negative $3800.42, reflecting a valuation regime classified as fair historically but currently pricing in excessive optimism.
The investment grade as of this refresh is D — solid business quality. High-tier business, D-tier valuation with 1803% downside to $-3800.42 fair value
Key Metrics at a Glance
- Revenue growth: +18.8% year over year
- Net margin: 15.1%
- Forward P/E: 20.1x
- Fair value upside: -1802.9% to our estimate of $-3800
Current price: $223.17
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Morgan Stanley remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MS research →](/stocks/MS)